<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Plasma antithrombin III (AT III) levels decrease early during <z:mp ids='MP_0001795'>Gram-negative</z:mp> <z:e sem="disease" ids="C0036690" disease_type="Disease or Syndrome" abbrv="">septicaemia</z:e>, and even a moderate decrease in this major inhibitor of the coagulation system is associated with serious <z:hpo ids='HP_0005521'>disseminated intravascular coagulation</z:hpo> (<z:chebi fb="0" ids="53092">DIC</z:chebi>) </plain></SENT>
<SENT sid="1" pm="."><plain>This study reports the efficacy of high dose (at least 250 units/kg) AT III replacement in three animal models of Escherichia coli endotoxaemia or <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteraemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Highlights of our findings are: 1 </plain></SENT>
<SENT sid="3" pm="."><plain>Endotoxaemic rat model: <z:chebi fb="0" ids="53092">DIC</z:chebi> occurs early, before the appearance of deleterious <z:hpo ids='HP_0001626'>cardiovascular abnormalities</z:hpo>; AT III prophylaxis attenuates <z:chebi fb="0" ids="53092">DIC</z:chebi>; and AT III prophylaxis increases permanent survival </plain></SENT>
<SENT sid="4" pm="."><plain>2 </plain></SENT>
<SENT sid="5" pm="."><plain>Endotoxaemic sheep pulmonary dysfunction model: AT III prophylaxis prevents the typical decrease in arterial oxygen partial pressure and AT III prophylaxis combined with alpha 1-proteinase inhibitor significantly attenuates indices of pulmonary dysfunction </plain></SENT>
<SENT sid="6" pm="."><plain>3 </plain></SENT>
<SENT sid="7" pm="."><plain>E. coli bacteraemic baboon model: AT III prophylaxis and treatment significantly attenuates indices of <z:chebi fb="0" ids="53092">DIC</z:chebi> and organ damage, and prevents <z:hpo ids='HP_0011420'>death</z:hpo> in an otherwise 100% lethal <z:mp ids='MP_0001794'>bacterial</z:mp> challenge </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion, prophylactic treatment with high doses of AT III may be efficacious in <z:mp ids='MP_0002054'>disease states</z:mp> of impending <z:chebi fb="0" ids="53092">DIC</z:chebi> such as <z:mp ids='MP_0001795'>Gram-negative</z:mp> <z:e sem="disease" ids="C0036690" disease_type="Disease or Syndrome" abbrv="">septicaemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Data presented herein demonstrate that plasma levels of AT III must be maintained at levels markedly higher than <z:mpath ids='MPATH_458'>normal</z:mpath> to be efficacious in animal models of <z:mp ids='MP_0001795'>Gram-negative</z:mp> endotoxaemia or <z:e sem="disease" ids="C0004610" disease_type="Disease or Syndrome" abbrv="">bacteraemia</z:e> </plain></SENT>
</text></document>